Biotech Values

[fid]

The drug doesn't have to reduce death in 30 days to have a meaningful benefit. Reducing non fatal mi is all it needs to do. As long as it doesn't increase death, which it shouldn't.


Your statement seems to be at great odds with the following, any thoughts?

http://circres.ahajournals.org/cgi/content/full/95/2/125

It is important to note that FDA approval requires improvement in morbidity and mortality; secondary end-points such as limitation of infarct size are not sufficient.

fid